The evaluation of toxicity and survival results of a phase II trial investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma
dc.contributor.author | Demir, G | |
dc.contributor.author | Buyukunal, E | |
dc.contributor.author | Mandel, N | |
dc.contributor.author | Demirelli, F | |
dc.contributor.author | Serdengecti, S | |
dc.contributor.author | Bese, N | |
dc.contributor.author | Yildirim, A | |
dc.contributor.author | Ober, A | |
dc.contributor.author | Ozguroglu, M | |
dc.date.accessioned | 2021-03-03T13:05:45Z | |
dc.date.available | 2021-03-03T13:05:45Z | |
dc.identifier.citation | Bese N., Yildirim A., Ober A., Ozguroglu M., Mandel N., Demir G., Demirelli F., Serdengecti S., Buyukunal E., "The evaluation of toxicity and survival results of a phase II trial investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma", 23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23), Amsterdam, Hollanda, 24 - 28 Ekim 2004, cilt.73 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_31f37d27-ff8c-4263-99f3-57752fab7a75 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/37941 | |
dc.language.iso | eng | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Nükleer Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.subject | RADYOLOJİ, NÜKLEER TIP ve MEDİKAL GÖRÜNTÜLEME | |
dc.title | The evaluation of toxicity and survival results of a phase II trial investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma | |
dc.type | Bildiri | |
dc.contributor.department | , , | |
dc.identifier.volume | 73 | |
dc.contributor.firstauthorID | 130296 |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [64839]